Slope

Is your organization ready for the changes that are going to impact your biospecimen management processes when the European Medicines Agency (EMA) officially adopts ICH E6(R3) on July 23, 2025? Failure to adapt could eventually result in: ➡️ Increased audit findings and regulatory scrutiny ➡️ Data integrity concerns that impact trial outcomes ➡️ Delays in study timelines due to noncompliant biospecimen ops ➡️ Financial and reputational consequences from failed inspections Read the blog below to stay ahead of the curve and ensure compliance.

The transition from ICH E6(R2) to ICH E6(R3) marks a pivotal shift in regulatory expectations for biospecimen management in clinical research. With an expanded emphasis on risk-based quality management, enhanced data governance requirements, and increased sponsor oversight responsibilities, organizations must evolve their internal processes to maintain compliance. Join Slope CEO, Rust Felix, alongside industry experts Edye Edens and Aman Khera on April 15th as they delve into how ICH E6(R3) will impact biospecimen management practices. Register here: https://hubs.la/Q03d9PDD0

Congratulations to Teal Health on unveiling landmark results from their SELF-CERV study! The data confirms that self-collected samples using the Teal Wand™ match clinician-collected samples — validating Teal's at-home cervical cancer screening as a preferred and viable alternative to in-person screening. At Slope, we’re proud to have supported Teal Health’s pivotal trial by providing our Biospecimen360™ software for biospecimen and inventory management — helping them hit their enrollment target 23% faster, giving them sample metadata access within 4.8 hours of sample collection on average, and eliminating inventory and sample-related deviations. This groundbreaking partnership helped Teal Health secure FDA Breakthrough Device Designation, paving the way for more accessible cervical cancer screening options. Click here to read Teal Health’s full press release: https://hubs.la/Q03cBSv00 Read our full case study to learn how Slope’s collaboration with Teal Health played a role in this achievement: https://hubs.la/Q03cBDjS0

🚀 Meet Brian Smith, Slope’s New VP of Product! 🚀 With a career spanning clinical operations, product management, and data management across leading labs and technology vendors, Brian brings a unique perspective to biospecimen management. In this Q&A, Brian shares: • Key trends shaping biospecimen logistics in clinical trials • The role AI will play in streamlining sample management • How Slope is evolving to meet the ever-changing needs of sponsors and sites 📖 Read the full Q&A here: https://lnkd.in/eWb8w3ph

Day 3 of #SCOPESummit got off to a strong start this morning as we presented on the power of agnostic data sharing with LabConnect and CellCarta. If you want to chat more about why a unified clinical ecosystem is the key to transforming #clinicalresearch, make sure you stop by this afternoon to see us on the show floor! You can find us at: • Booth #1216 – Slope • Booth #908 – LabConnect • Booth #1221 – CellCarta #SCOPE2025

We're ready for another great day at #SCOPESummit! Don't forget to catch our panel this morning at 9:55am in Suwannee 15. We hope to see you there!

We're feeling the excitement of #SCOPESummit this morning at Booth #1216! Stop by to learn more from our team about how we connect sponsors, sites, labs, and CROs with our vendor-agnostic biospecimen lifecycle software. #SCOPE2025

We're less than one week away from one of our favorite shows of the year: #SCOPESummit! With so many enlightening presentations ahead, we're excited to be a part of this year's jam-packed agenda. Join our very own Mark Melton, CellCarta's Anne MacNeil, and LabConnect's John Mapel for this joint presentation. You'll walk away with an understanding of the: ➡️ Challenges of a fragmented clinical ecosystem on data sharing and quality ➡️ Status quo and need for agnostic data sharing ➡️ Existing case studies on collaborations for inventory and sample metadata continuity ➡️ Key to transforming clinical research #SCOPE2025 #Biomarkers #PrecisionMedicine #Biospecimens

We’re thrilled to announce that CellCarta has launched their new Kit Inventory Portal, powered by Slope! This innovation significantly streamlines kit inventory management for sponsors and research sites who leverage CellCarta for kitting. Today, 83% of NCI-designated cancer centers already rely on Slope’s free inventory solution to maintain efficient study operations. We’re excited to continue expanding this solution to benefit even more research sites and sponsors, driving better clinical trials. Learn more: https://lnkd.in/eaKPKdYE

2024 flew by. From groundbreaking collaborations to exciting advancements in biospecimen management, this year has been a testament to the power of innovation in our industry. Together, we can continue building a future where patients are paramount in clinical research. From the Slope team to you, we wish you and yours a safe and happy holiday season!